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KEY POINTS 
 Heart failure is associated with significant morbidity and mortality 
 Biomarkers are commonly used for diagnostic and prognostic purposes 
 Protein-based biomarkers have been identified to aid clinicians for early diagnosis of 
heart failure and provide added information for prognosis  
 Proteomics is an ever-expanding field that employs techniques to measure a wide-
range of proteins and peptides in search to identify potential protein biomarkers 
SYNOPSIS 
Heart failure (HF) is associated with significant morbidity and mortality. Biomarkers are used 
to assist clinicians with timely diagnosis, prognosis and risk prediction of patients for 
personalized treatment. Using modern proteomic methods such as mass spectrometry, an 
increasing number of novel biomarkers have been identified that further aid clinicians in the 
early diagnosis and outcome prediction of HF. This review focuses on the array of common 
and novel protein-based biomarkers which provide diagnostic and prognostic information in 
HF. 
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Introduction 
It is estimated that in excess of 20,000 protein-coding genes are responsible for the presence 
of more than one million proteins found in biological matrices (1). The measurement of these 
proteins, commonly in plasma, serum, urine, saliva and tissue samples (2), has provided 
critical advancements in medical science through the development of diagnostic and 
prognostic assays for patients presenting with, or at risk of, a multitude of diseases (3). The 
use of protein measurements has been particularly beneficial for the assessment of 
cardiovascular disease, with notable inclusion of natriuretic peptides and troponin isoforms 
in clinical decision-making for heart failure (HF) (4) and acute coronary syndromes (ACS) (5), 
respectively. Clinical measurements of endogenous biological substances, such as proteins, 
lipids and metabolites, are commonly referred to as biomarkers and provide 
pathophysiological information through an associative or direct mechanistic interaction with 
the diseased system, organ or tissue (6). The relationships of protein biomarkers with disease 
allow physicians to assess the presence, severity, and/or prognosis of a condition with 
improved precision and accuracy (7). 
The progression in medical diagnosis and treatment of HF has been heavily influenced by the 
inclusion of protein biomarker analyses, with measurement of natriuretic peptides commonly 
employed in hospitals worldwide (8). HF is a major worldwide epidemic associated with high 
morbidity, mortality, and healthcare costs affecting more than 23 million, especially those 
aged ≥65 years (9); therefore, any improvements in diagnosis, prognosis and therapeutic 
monitoring using protein measurements provide direct improvements in patient care and 
outcome, as well as economic burden. Difficulties in HF diagnoses exist due to the 
multifactorial pathophysiology (such as cardiac stress and injury, neurohormonal activation 
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and endothelial congestion), and that the signs and symptoms may not arise during early 
stages of the disease (10, 11). Current guidelines suggest patients presenting with suspected 
HF should be referred measurement of circulating natriuretic peptides to aid in diagnosis of 
the condition (12). 
The development and pathophysiology of HF is associated with changes in the expressions of 
an array of metabolic, signaling and structural proteins (13). Although there are a number of 
protein-based assays currently used in the clinical laboratories, extensive research is being 
performed to isolate and identify novel protein biomarkers associated with HF in a bid to 
improve sensitivity and/or specificity of biomarker information. Leading these discovery-led 
investigations are mass spectrometry (MS)-based assays which involve a non-targeted 
approach to protein measurement and fall under the remit of proteomics. These assays 
measure all detectable proteins that are expressed by a cell, tissue or organism, known as the 
proteome, and reflect levels present at the time of sample collection (14, 15).  
Proteomic Biomarker Discovery 
For discovery-led proteomics investigations, the initial phase employs methods using either a 
widespan-targeted or non-targeted approach in order to measure a large number of proteins 
and/or peptides from various biological sample types. This generates a list of numerous 
proteins that are identified as associated with the condition being investigated and, therefore, 
selected as candidate proteins for subsequent verification experiments. Although many 
candidate protein biomarkers may be identified through these experimental workflows, very 
few survive the rigorous validation processes leading to the development of high-throughput 
assays for measurement (16). Mass spectrometry (MS) is the most widely used 
instrumentation for non-targeted discovery and identification of potential protein 
5 
 
biomarkers. It allows for quantitative and qualitative analysis, peptide sequencing and 
identification with great accuracy and sensitivity (17). Proteomic workflows can vary greatly 
across investigations, including sample preparation, chromatographic gradients and inclusion 
of complementary analytical techniques such as ion mobility spectrometry. Furthermore, 
differences across studies in data processing and statistical testing can lead to 
misidentification or masking of candidate biomarkers. These widely varied approaches 
provide limitations in that biomarker identification may not be reproducible across multiple 
methods, complicating the validation process for novel protein biomarkers. Typically, MS 
method workflows include fractionation to crudely separate proteins in the sample, removal 
of highly abundant proteins such as albumin in plasma samples, further separation of each 
fraction using liquid chromatography, and MS using electrospray ionization (ESI) in positive 
ion mode coupled to accurate mass analyzers such as time-of-flight (ToF) and orbitrap (18). 
Alternatively, gel-based approaches are initially employed to separate proteins by their 
isoelectric point and then by mass using polyacrylamide gel (SDS-PAGE), followed by staining, 
excising, digesting using trypsin and analysis by MS (19). Following identification of candidate 
biomarkers, mass spectral data are cross-referenced with large-scale databases to confirm 
protein identification. Errors in protein quantitation in global discovery techniques can be 
associated throughout the analytical workflow from samples preparation to analysis. To assist 
in reducing these errors, isotopic labelling of internal protein standards can allow for relative 
quantitation of multiple proteins. Examples of these include metabolic labelling (15N) and 
isotope-coded affinity tags (ICAT), however, they lack in accuracy and precision and more 
reliable approaches for sample-wide quantitation are required (20). 
Traditional non-targeted MS based methods are important in candidate biomarker 
identification, however complex sample preparation and analysis steps create a time 
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consuming process that limits the throughput required for larger-scale validation studies. 
Once a list of candidate biomarkers is produced, a shift toward targeted MS approaches 
allows for improved specificity, reproducibility and quantitation of candidates, while also 
drastically reducing the analytical run time. A commonly employed approach for targeted MS 
is to develop assays using selective or multiple reaction monitoring (SRM/MRM), where a 
single ion (SRM) or up to five fragment ions (MRM) are monitored in association with a 
specific product ion, typically using a triple quadrupole MS system which is able to provide 
enhanced discriminating power, leading to increased sensitivity, absolute quantitation (21, 
22) and improved cross-compatibility between instrumentation (23). Aside from ESI-MS, 
matrix-assisted laser desorption ionization (MALDI) ToF based MS is employed for targeted 
MS where proteins of interest can be isolated using immunoprecipitation or LC prior to 
spotting onto a target plate for analysis. Several targeted protein analyses using MALDI have 
been reported (24, 25), including an application in clinical studies (26, 27). Prior to 
commercialization, targeted protein experiments must replicate the results observed from 
the non-targeted investigations, as well as expanding to larger sample cohorts including 
diseased and non-diseased populations to validate as a biomarker of a condition and to 
understand normal ranges and potential disease cut-off values. 
As protein expressions exhibit multifaceted temporospatial characteristics driven by 
responses to physical and/or biological stimuli, there are several complexities involved in the 
process of identifying a novel protein biomarker. In order to confirm the utility of a candidate 
biomarker for a clinical purpose, several steps must be achieved including discovery, 
qualification, verification, optimization and validation, followed by commercialization and 
distribution of assays (28) (Figure 1). Although the discovery of novel proteins is driven by 
mass spectrometric methods, validation and commercialization more frequently involve 
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traditional antibody-based techniques such as ELISA, Western Blotting and immunoblotting, 
with the less common use of MS-based methods in a clinical setting dictated by obstacles in 
regulatory approval and cross-site/equipment reproducibility (29). Regardless of the most 
suitable analytical method, a successful biomarker must be easily measured, low cost, 
patient-friendly, and show high levels of sensitivity and specificity for their purpose (e.g. 
diagnosis, prognosis) (30). 
This review intends to highlight the current clinical uses of protein biomarkers in HF (Figure 
2) and discuss the application of targeted and non-targeted proteomic investigations to 
discover and develop novel biomarkers centered on using a personalized medicine approach 
for improved prognostic information.  
Markers of cardiac stress 
BNP/NTproBNP 
B-type natriuretic peptide (BNP) is perhaps the most widely used biomarker for cardiac stress. 
It is a central component in cardiovascular homeostasis and is released from the 
cardiomyocytes, primarily located in the ventricles, in response to stress and stretch of the 
cardiac muscle (31). After binding to specific receptors, BNP is activated and drives a 
reduction in systemic vascular resistance, antagonizes the actions of the renin-angiotensin-
aldosterone system (RAAS), and promotes vasodilation and natriuresis (32). BNP has been 
studied extensively for its role as a diagnostic (33-35) and prognostic (36-38) biomarker in HF, 
including both chronic patients and acute decompensated admissions. However, an 
important limitation of BNP for HF diagnosis is that circulating levels may become elevated in 
response to alternative disorders such as renal dysfunction, left ventricular hypertrophy and 
right ventricular dysfunction (39). Furthermore, as factors such as sex, age and body mass 
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index are also associated with fluctuations in BNP levels, accurate interpretation of circulating 
concentrations is crucial (40). 
In addition to uses in diagnosis and prognosis, BNP has shown utility for the monitoring of 
patients treated with diuretics and vasodilators such as ACE inhibitors (41), angiotensin-II 
receptor antagonists (42), and aldosterone inhibitors (43). Circulating BNP levels are known 
to fall rapidly following successful treatment strategies, therefore repeat measurements of 
BNP concentrations provide an observation of responses to medical interventions. 
Although widely used in clinical analysis, BNP exhibits a short half-life (approximately 20 
minutes) when present in the circulation (44) and, therefore, care must be taken during the 
sampling and storing of blood samples. N-terminal proBNP (NTproBNP) is released in 
conjunction with BNP and is considered as a more stable alternative due to its longer half-life 
(45). NTproBNP has reported similar characteristics to BNP as a biomarker for diagnosis (46-
48), prognosis (42, 46, 49) and guided treatment (50) in HF.  
When studied in direct comparison, BNP and NTproBNP show comparable utility for diagnosis 
(42), prognosis (51, 52) and biomarker-guided therapy (53) in chronic HF, with reductions in 
all-cause mortality reported with titration of therapies based on repeat measurements. 
Circulating levels of these natriuretic peptide biomarkers are increased in HF and are strongly 
associated with disease severity and myocardial stretch (54). Studies, such as the Valsartan 
Heart Failure Trial (Val-HeFT), have also shown BNP and NTproBNP to provide superior 
prognostic information when compared to alternative neurohormonal markers of risk (55).  
Molecular forms of BNP 
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There have been recent research efforts to further understand the degradation pathways of 
BNP and, with its short half-life in circulation, experiments have also reported the presence 
of its molecular forms. These molecular forms are truncated BNP peptide chains that are 
synthesized by the proteolysis of end-chain amino acids and have been identified in the 
circulation of HF patients (e.g. BNP 3-29, 3-30, 4-29, 5-29 etc.), with BNP 3-32, 4-32 and 5-32 
reported as the most commonly present (56). These molecular forms have recently emerged 
as potential biomarkers for HF, with the major forms previously implicated in ischemic heart 
disease (57), a major risk factor for development of HF. Furthermore, molecular forms have 
been reported to more closely associate with clinically measured BNP levels in comparison to 
the parent BNP molecule (BNP 1-32). This suggests that the specificity of clinical BNP assays 
is not unique to BNP 1-32, and that the combination of intact and molecular forms of BNP is 
a more accurate representation of circulating BNP measurements (58). More recently, 
molecular forms of BNP have shown superior or comparable prognostic qualities to NTproBNP 
for risk stratification of acute HF patients. BNP 3-32, 4-32, and notably 5-32 were able to 
independently predict adverse outcome of patients at 6 months and 1 year, outlining its use 
as a biomarker to guide outpatient management (27). However, direct mechanistic actions of 
these truncated forms, along with the dynamics and kinetics of their degradation pathways 
are not currently understood and remain areas of current research.  
ANP 
Atrial natriuretic peptide (ANP) is primarily secreted from the atria and has similar 
physiological properties to BNP. It is thought to play a role in early HF by preserving the 
compensated state of left ventricular dysfunction (59). Although reported to be a prognostic 
indicator in HF, studies have reported ANP as inferior to BNP primarily due to its decreased 
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stability in circulation and its insensitivity to levels of HF severity (60, 61). Other forms of ANP, 
such as N-terminal ANP (N-ANP/NTproANP) and mid-regional pro-ANP (MRproANP), have 
also been shown to offer diagnostic and prognostic roles in HF (61-63). MRproANP has far 
greater stability in circulation and therefore could prove more suitable for use as a biomarker 
in comparison to ANP. An investigation using The Biomarkers in ACute Heart Failure (BACH) 
cohort reported that MRproANP was a suitable diagnostic and prognostic biomarker in 
dyspneic patients, with results comparable to BNP (63). Furthermore, additional studies have 
also indicated that MRproANP provides additive prognostic information to NTproBNP in 
chronic HF (64) and as a diagnostic marker of acute destabilized HF in patients with dyspnea, 
again reporting comparable results to the use of both BNP and NTproBNP (65). 
ST2 
ST2 is a member of the interleukin receptor (IL-1) family and has been identified as the target 
for IL-33 which is expressed under biochemical stress of the heart (66). ST2 is basally 
expressed by cardiomyocytes and is detectable in circulation in its soluble form which is 
elevated in response to mechanical stress of the heart (67). Its utility has been recognized in 
HF as an independent predictor of mortality or need for transplantation in severe chronic HF 
patients (NYHA class III/IV) (67), as well as providing prognostic information for acute HF 
patients when combined with natriuretic peptides (68), suggesting applicability as a 
biomarker in combination with current clinical testing strategies (e.g. BNP and NTproBNP). 
Furthermore, although NTproBNP showed improved diagnostic accuracy for patients with 
acute HF, the PRIDE (Pro-Brain Natriuretic Peptide Investigation of Dyspnea in the Emergency 
Department) study showed that ST2 was a suitable biomarker to predict 1-year mortality in 
dyspneic patients, irrespective of a positive or negative diagnosis of acute destabilizing HF 
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(69), offering a more generalized biomarker function that can be further refined when 
applying a multi-biomarker approach.  
MRproADM 
Adrenomedullin (ADM) is a peptide hormone that has natriuretic, vasodilatory and 
hypotensive effects on the heart, with plasma concentrations elevated in response to these 
effects, such as seen in chronic HF (70). However, since ADM is unstable in circulation, its mid-
regional pro-hormone fragment (MRproADM) is often measured to perform an indirect 
quantification (71). It has reported a varied role in prognosis, providing information for short- 
(30 days) and long-term (4 years) prognosis, but less success for mid-range predictions of 
outcome (1 year) (72). MRproADM has also been successfully demonstrated as a prognostic 
biomarker for acute HF patients presenting with dyspnea (73). In this study it was reported as 
a superior biomarker to both BNP and NTproBNP for the short-term prediction of mortality 
(90 days) as well as for subsequent patient rehospitalization (73). Data suggest it has a suitable 
role for use in HF prognosis, however, further investigations to confirm its superiority to 
current biomarkers are warranted.  
Markers of inflammation or injury 
Troponin 
Troponin proteins are found in cardiac and skeletal muscle tissue and are involved in the 
regulation of actin and myosin interactions during muscle contraction. Troponin I (cTnI) and 
T (cTnT) have unique isoforms that exist only in cardiac muscle allowing the measurement of 
these specific isoforms to provide information in cardiovascular disease, notably as diagnostic 
biomarkers for ACS (74). However, development of high-sensitivity troponin assays have 
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further allowed the measurement of elevated cTnI/cTnT levels in HF patients (75, 76), with 
increased concentrations associated with poor outcome. High-sensitivity assays for cTnT have 
been applied for prognosis in chronic HF, with circulating concentrations able to predict 
mortality and hospitalization in stabilized patients (77). Furthermore, cTnT has been shown 
as a suitable marker to reflect myocardial damage in severe chronic HF (78), to risk-stratify 
patients on admission for subsequent mortality and morbidity (79), and to identify patients 
at high-risk of disease deterioration (80). For acute decompensated HF in the absence of ACS, 
cTnT is a prognostic marker for short- and long-term outcomes (81).  
In addition, cTnI has been shown to reflect elevated BNP levels, impaired hemodynamics and 
worsening of left ventricular dysfunction (82). For acute admissions, serial changes in cTnI 
levels over 90 days were functional in predicting increased likelihood of mortality and 
rehospitalization (83). When used in combination with BNP measurements, cTnI 
measurements on admission were shown to predict in-hospital mortality, and increasing 
concentrations were associated with risk of death in a large-scale registry cohort (The Acute 
Decompensated Heart Failure National Registry {ADHERE}) (84, 85). 
H-FABP 
Heart-type fatty acid-binding protein (H-FABP) is a small cytosolic protein involved in 
transporting long-chain fatty acids in the myocardium and is released in response to 
myocardial damage (86), indicating its potential as a sensitive biomarker for acute myocardial 
infarction (MI) (87). H-FABP concentrations are known to be increased in congestive and 
chronic HF (88), and reported to be a more sensitive than troponin to detect myocardial 
damage and identify patients at high-risk (86). Initial investigations have been performed to 
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understand the role and/or association of H-FABP in HF, however further studies are required 
to assess its utility in comparison with current clinical measurements. 
CRP 
C-reactive protein (CRP) is a traditional marker of inflammation and high concentrations are 
commonly associated with mortality in acute MI patients. However, studies have also shown 
increased CRP levels in HF patients, reflecting myocardial damage (89) and associations with 
HF severity, mortality and morbidity (90), and rehospitalization (91). Data indicate that CRP 
can be used as a predictor for deterioration of heart function, however it has also been 
reported to show no statistical association with left ventricular ejection fraction, providing 
complications for its suitability and specificity as a biomarker in HF (92). 
TNF-α 
Tumor necrosis factor-α (TNF-α) is a cytokine involved in inflammation and has been reported 
to exhibit elevated levels in chronic HF (93). TNF-α has also been implicated in newly 
diagnosed HF patients, with elevated levels associated with abnormal left atrial dysfunction, 
and advanced left ventricular diastolic and systolic dysfunction (94). Further associations have 
been reported with NYHA class and disease severity (95), alongside the use of TNF-α as a 
predictor of mortality in advanced HF (96).  
IL-6 
Interleukin-6 (IL-6) is also a cytokine involved in inflammation, but has additional 
cardiovascular properties through regulation of cardiomyocyte hypertrophy and apoptosis 
(97). Cardiac IL-6 expression is reported to increase in advanced HF, providing suggestion for 
its potential role in prognosis (98). In addition, elevated IL-6 levels have been associated with 
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left ventricular dysfunction prior to HF diagnosis, highlighting its potential utility as a risk 
marker for the onset and progression of HF (99). This prognostic ability has been confirmed 
in acute HF for prediction of short- and long-term mortality, both as a sole biomarker and in 
a multi-marker approach when combined with NTproBNP (100). Furthermore, IL-6, along with 
CRP and IL-4, concentrations have been shown to increase during a coronary event, returning 
to pre-event levels as symptoms of HF subside over time. This observation indicates a 
potential role for IL-6 in differentiating between the decompensated and compensated state 
(101). 
Markers of neurohormonal activation 
Copeptin 
Pre-pro-vasopressin is preteolytically cleaved into copeptin, neurophysin II and vasopressin, 
with the latter also known as antidiuretic hormone that has a prominent  role in fluid 
homeostasis and shown to be related to the severity of HF (102). However, vasopressin is 
known to exhibit instability in circulation and therefore is troublesome for clinical 
measurements. On the other hand, copeptin is considered to have a high stability and is 
released in equimolar concentrations to vasopressin, allowing a more reliable and 
reproducible alternative for indirect measurement of vasopressin (103). Research into the 
clinical role of copeptin as a prognostic biomarker has been compared to measurements of 
natriuretic peptides and initial indications suggest it offers a superiority in prediction for 14- 
and 90-day mortality in acute admissions (73, 104) and longer-term prediction at 24 months 
for patients across various stages of disease (105), as well as for those with advanced HF (106). 
Although a relatively contemporary biomarker for HF, data highlight copeptin measurements 
as a potential clinical tool for risk-stratification, particularly in acute cases.  
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MMPs 
Matrix metalloproteinases (MMPs) are a family of zinc-dependent protease enzymes required 
for normal tissue remodeling, and mediating collagen metabolism and extracellular matrix 
(ECM) homeostasis (107). Four common classes of MMP’s have been identified: gelatinases 
(MMP-2 and MMP-9), collagenases (MMP-1 and MMP-8), stromelysin (MMP-3) and 
matrilysin (MMP-7), all of which are regulated by tissue inhibitors (TIMPs) (108). 
Elevated MMP-9 and MMP-2 concentrations have been reported in HF patients (105), with 
the latter associated with mortality (109). Conversely, MMP-8 has been shown to exhibit a 
decreased concentration in chronic HF patients (110). Although there are variable alterations 
of MMPs in patients and more extensive research is required to identify their individual 
suitability for prognostic investigation, data do suggest that they offer additional information 
when included within a multi-biomarker panel (111). These panel risk scores can improve the 
information available to identify disease process and HF risk in-line with changes to ECM 
collagen homeostasis and activity of enzymes of remodeling.  
Markers of remodeling 
Galectin-3 
Galectin-3, a member of the lectin family, has shown to be implicated in multiple aspects of 
HF physiology, including inflammation and ventricular remodeling. It is secreted by activated 
macrophages which proliferate and cause cardiac fibrosis (112, 113), and has been 
demonstrated to provide a positive role as a prognostic marker of HF (114, 115). Elevated 
gelactin-3 levels have been associated with an increased risk of HF and mortality (116), with 
a two-fold increase in levels associated with a two-fold increase in risk of death or 
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rehospitalization over an 18-month period (114). Furthermore, increased concentrations 
have also been associated with adverse outcome in patients with preserved ejection fraction 
(HFpEF) (117). As with many proteomic biomarkers of HF, study into the role of gelactin-3 
requires further research, but initial data offer potential as a marker to stratify patients for 
HF with or without remodeling. 
GDF-15 
Growth differentiation factor-15 (GDF-15) is a stress-responsive, transforming growth factor 
beta-cytokine involved in inflammatory and apoptotic pathways of tissue injury. It is an 
emerging marker of cardiac dysfunction and elevated levels of GDF-15 have been shown to 
identify high-risk cardiovascular disease patients (118, 119). Elevated GDF-15 has 
demonstrated mortality prediction in patients with chronic HF, with increased expression of 
GDF-15 linked to the promotion of protective mechanisms for inhibition of apoptosis, 
hypertrophy and adverse remodeling (120). Elevated levels have also reported prognostic 
utility in both patients with reduced (HFrEF) and preserved (HFpEF) ejection fraction, adding 
to current markers such as troponin and NTproBNP (121, 122). For acute decompensated HF, 
elevated GDF-15 concentrations have shown prognostic value for predicting mortality and HF 
rehospitalization at 1-year, supported by twenty-one original studies (123, 124).  
Markers of associated comorbidities 
Cystatin C 
Cystatin C is a small protein molecule that is involved in the extracellular inhibition of 
cathepsins. It is removed from circulation through the kidneys, thus providing biomarker 
information for renal dysfunction and therefore an interest within cardiovascular disease 
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(125). Cystatin C has shown prognostic capabilities in chronic HF patients as well as those with 
reduced ejection fraction (126-128). These positive relationships with adverse outcome in HF, 
as well as providing information on dysfunction in the renal system, signify cystatin C as a 
useful biomarker for a combinatory view of cardiovascular disease and its comorbidities. 
NGAL 
Neutrophil gelatinase-associated lipocalin (NGAL) is an innate antibacterial factor protein of 
the lipocalin family, initially found to be expressed in neutrophils and later in kidney tubular 
cells. In kidney dysfunction, NGAL has been shown to be an early marker of injury in animal 
models and detectable in blood and urine following acute kidney injury (129, 130).  
In chronic HF patients, NGAL concentrations were found to be increased when compared to 
healthy subjects (131, 132). However, their applicability as a prognostic marker was proven 
to be inferior to currently established protocols (e.g. NTproBNP) (133). In acute cases, the 
GALLANT [NGAL EvaLuation Along with B-type NaTriuretic Peptide (BNP) in acutely 
Decompensated Heart Failure] trial indicated that NGAL was a strong short-term (30 days) 
prognostic predictor of HF-related outcomes (134).  
Procalcitonin 
Procalcitonin is a precursor peptide of calcitonin and a diagnostic marker of bacterial 
infections, such as in pneumonia (135), with elevated levels also measured in HF patients 
(136). Elevated procalcitonin concentrations were able to predict the risk of long-term death 
and rehospitalization in acute admissions, irrespective of bacterial infections (137), and were 
observed to be in-line with disease severity for chronic patients (138). Additionally, serum 
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procalcitonin concentrations provided diagnostic information for HF with high sensitivity and 
specificity (139).  
Contemporary proteomic biomarkers 
Recent research has led to an increased number of protein biomarkers that show promise in 
diagnosis and prognosis of HF conditions. For example, Proenkephalin A (PENK) and 
Chromogranin A (CgA) are proteins measured in the circulation that have shown utility as 
biomarkers in HF, and efforts to validate these for transition into a clinical setting are 
underway. PENK is a small endogenous opioid peptide which is cleaved to produce 
enkephalin. Studies have shown that enkephalins are released from non-neuronal tissues, 
including the kidneys and heart, in response to ischemia (140). In chronic and acute HF, PENK 
is associated with glomerular function, but does not offer significantly additive prognostic 
information in addition to current biomarkers of renal function (141). However, it has 
demonstrated useful prognostic information for hospitalization or mortality in stable HF 
patients (142). In addition, PENK concentrations have shown predictive capabilities for in-
hospital mortality in acute HF patients, as well as indicating those at risk of worsening renal 
function (143). CgA is a prohormone produced in various tissues including the heart. 
Hyperglycosylations of CgA lead to its impaired conversion to catestatin, an action found to 
be associated with acute HF outcomes (144). Mixed prognostic quality has been reported in 
the literature with studies showing CgA to be associated with the severity of chronic HF and 
a prognostic marker for mortality (145), but providing no additive information for prognosis 
when compared to established protocols and biomarkers (146). In addition to CgA, 
chromogranin B (CgB), which is co-localized with CgA, has also shown an increase in 
concentrations to follow severity and development of HF (147). 
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Although PENK and CgA have been taken forward to extended validation studies, discovery-
focused proteomics experiments have identified a number of circulating proteins as potential 
novel biomarkers for HF. The use of urine sampling as a less-invasive alternative to the 
traditional blood draw has led to an interest in highlighting urinary proteins for diagnostic 
testing in HF. Two proteins, insulin-like growth factor binding protein 2 (IGFBP-2) and 
orosomucoid 1 (ORM1), have been reported to possess diagnostic potential providing 
additive information to current biomarkers such as BNP for IGFBP-2 (148), as well as 
increasing concentrations in-line with severity of chronic HF and good diagnostic sensitivity 
(95%) and selectivity (85%) for ORM1 (149). These are examples of proteomic biomarkers that 
have provided initially positive associations, but further validation in extended experiments 
is required.  
Other novel protein discoveries have been supported with initial mechanistic and/or clinical 
investigations and therefore are following the required pathway for translation into a clinical 
setting. Leucine-rich α2-glycoprotein (LRG) was reported to have an exaggerated expression 
in patients with a measured BNP of ≥100 pg/mL, and provided similar diagnostic statistics to 
BNP (150). In addition to this, the authors demonstrated cardiac myocytes to be the origin of 
LRG release and more recently it was observed that LRG was active in suppressing adverse 
remodeling post-myocardial infarction (151), and that LRG release in HF may be in response 
to pressure overload. Calcium-binding proteins A8/9 (S100A8/9) have also been reported to 
exhibit an upregulated expression as a protective mechanism in HF development, with an 
observed contribution to the anti-HF effect of hypertrophic preconditioning (152). In addition 
to their mechanistic interactions, S100A8/9 have also been shown to provide predictive 
qualities for mortality in elder patients with severe HF (153). Similarly, circulating heat shock 
protein 70 (HSP70) has been shown to rise in concurrence with cardiac expression (154) and 
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HF severity (HF) (155), and has been implicated as a potential biomarker for early diagnosis 
of HF (155). 
Although the prior examples of novel biomarkers have undergone initial stages of mechanistic 
and clinical validation, more recent experiments have indicated further potential biomarkers 
that remain at the discovery phase. For example, quiescin Q6 (QSOX1) has shown promising 
signs of a biomarker that is specific to acute decompensated HF with dyspnea, with reduced 
and comparable levels measured in chronic HF patients and healthy volunteers (156). QSOX1 
has been shown to increase in the left ventricle in an animal HF model (157) and provides 
diagnostic qualities that are equal to BNP and NT-proBNP (156), with increased specificity 
over natriuretic peptides for diagnosis of acute decompensated HF in patients, irrespective of 
the presence of previous stable HF.  
Many candidate proteomic biomarkers for HF have been discovered and are still in the 
research phase to determine their roles in HF. Limited information regarding their additive 
role as biomarkers in HF is available and further research for their capacity is required. 
Extending from single biomarker analyses, proteome-wide investigations have provided 
insight into multi-biomarker models to predict future disease developments. A notable 
example was presented by Hollander et al. who identified a list of 17 candidate protein 
biomarkers that, when combined with BNP measurements, were able to provide 97% 
sensitivity and 100% specificity for classifying patients on recovery from cardiac transplants 
(158). This provides an exciting opportunity to provide outpatient screening to monitor 
response to HF treatments but requires extensive additional testing to validate its 
applicability for everyday clinical use.  
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Summary 
A wide range of protein-based cardiac biomarkers have shown success in diagnostic and 
prognostic applications, with several already established as routine measurements in clinical 
laboratories. Extensive research efforts are currently underway to enhance our knowledge of 
protein-cardiovascular disease interactions, led by proteomic-based organizations such as 
Human Proteome Organization (HUPO). The flagship venture has been The Human Proteome 
Project (HPP) that is looking to map the entire human proteome to further our understanding 
in the localized and systems biology of proteins and protein-protein interactions for 
diagnostic, prognostic and therapeutic roles in disease (159). In particular, HUPO has 
emphasized the need to develop open-access databases that allow the sharing of proteomics 
research data across equipment and institutions to detail the human proteome library (160). 
The advancement of technologies, such as mass spectrometry, which complement traditional 
enzyme-based assays have allowed the development of highly sensitive  and selective 
methods with the ability to measure multiple relevant biomarkers in a high-throughput 
manner. Although at a stage of infancy for translation to functional clinical laboratories, these 
methods offer potential for future advancements in breadth and depth of clinically-relevant 
biomarkers. In addition, the use of multiple ‘omics-based investigatory pathways, including 
proteomics, metabolomics, lipidomics and genomics, allow for the discovery and validation 
of novel biomarkers that provide improved clinical information to patients in cardiovascular 
disease and beyond. An example of this approach includes the focus of implementing the 
combination of protein and metabolite biomarkers to improve risk-stratification, with recent 
demonstration of enhanced prognostic capabilities in chronic and acute HF when combining 
BNP/NTproBNP with trimethylamine N-oxide, a metabolite biomarker linked to gut microbial 
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breakdown of dietary molecules (161, 162). Continued efforts for biomarker discovery and 
validation offer the promise to unearth novel and contemporary molecules for application in 
personalized and precision medicine, with the potential to lead to improved prognosis, 
treatment and early diagnosis of conditions at the center of public health concerns. 
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Figure 1  Protein biomarker discovery pipeline of novel candidate biomarkers 
 
ELISA, enzyme-linked immune-sorbent assay; LC-MS, liquid chromatography mass 
spectrometry; LC-MS/MS, liquid chromatography tandem mass spectrometry; MRM, multiple 
reaction monitoring  
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Figure 2 Protein biomarkers of heart failure and their various pathophysiological 
associations  
 
ANP, atrial natriuretic peptide; BNP, B-type natriuretic peptide; CRP, C-reactive protein; GDF-
15, growth differentiation factor-15; H-FABP, heart-type fatty-acid binding protein; IL-6, 
interleukin-6; MRproADM, mid-regional pro-adrenomedullin; NGAL, neutrophil gelatinase-
associated lipocalin;  NTproBNP, N-terminal pro B-type natriuretic peptide; PENK, 
proenkephalin; TNF-α, tumour necrosis factor-α 
 
